Scilex Holding Co SCLX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Scilex Holding Co (SCLX) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to June 30, 2026 it had revenue of $32M and net income of -$465M, a net margin of -1469.8%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -106%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 28% below the current price.
About Scilex Holding Co
Scilex Holding Co is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $24M in 2020 to $30M in 2025, growth of about 5.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 68% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $32M | $30M | $57M | $47M | $38M | $31M | $24M |
| Net income | -$465M | -$374M | -$73M | -$114M | -$23M | -$88M | -$48M |
| Free cash flow | -$18M | $4M | $19M | -$21M | -$21M | -$29M | -$31M |
| EPS (diluted) | $-49.70 | $-36.48 | $-8.05 | $-16916.31 | $-2246.70 | $-8854.63 | $-4.76 |
| Net margin | -1469.8% | -1236.4% | -128.7% | -244.6% | -61.4% | -282.4% | -201.7% |
| ROIC | — | — | — | — | -106.2% | — | -188100.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Scilex Holding Co stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 28% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Scilex Holding Co pay a dividend?
Not currently.
Is Scilex Holding Co a good stock to buy?
We do not give buy or sell advice. Scilex Holding Co scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.